Compare NUVL & WH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | WH |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 6.4B |
| IPO Year | 2021 | 2017 |
| Metric | NUVL | WH |
|---|---|---|
| Price | $123.50 | $87.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $134.75 | $94.10 |
| AVG Volume (30 Days) | ★ 4.2M | 1.3M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.04% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.80 |
| Revenue | N/A | ★ $1,429,000,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | $1,239.49 | $5.83 |
| P/E Ratio | ★ N/A | $107.66 |
| Revenue Growth | N/A | ★ 1.49 |
| 52 Week Low | $71.14 | $69.21 |
| 52 Week High | $123.69 | $92.69 |
| Indicator | NUVL | WH |
|---|---|---|
| Relative Strength Index (RSI) | 66.42 | 60.63 |
| Support Level | $97.99 | $75.75 |
| Resistance Level | $123.62 | $90.35 |
| Average True Range (ATR) | 0.58 | 2.95 |
| MACD | 0.66 | 0.73 |
| Stochastic Oscillator | 99.45 | 91.90 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
As of Dec. 31, 2025, Wyndham Hotels & Resorts operates 869,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Ramada is the largest brand, representing around 14% of all rooms, with Days Inn (13%) and Super 8 (10%) the next two largest brands, as of the end of 2025. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represented 58% of total rooms in 2025.